Spots Global Cancer Trial Database for A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
Official Title: A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
Study ID: NCT05683171
Conditions
Study Description
Brief Summary: To find a recommended dose of valemetostat that can be given in combination with rituximab and lenalidomide to patients with follicular lymphoma. The safety and effects of this drug combination will also be studied
Detailed Description: Primary Objectives: Phase 1 --Evaluate the safety and tolerability of valemetostat in combination with R2 in subjects with R/R FL and determine the recommended phase 2 dose (RP2D) for evaluation in phase 2. Secondary Objectives: Phase 1 * Evaluate the efficacy of valemetostat in combination with R2 in R/R FL * Evaluate the pharmacokinetics (PK) of valemetostat in combination with R2 Exploratory Objective: Phase 1 * Evaluate pharmacodynamic profile of valemetostat * Evaluate the efficacy of valemetostat in combination with R2 in R/R FL Primary Objective: Phase 2 --Evaluate the efficacy of valemetostat in combination with R2 in R/R FL Secondary Objective: Phase 2 * Evaluate the ORR * Evaluate the DOR * Evaluate the time to next anti-lymphoma treatment (TTNT) * Evaluate the safety and tolerability * Evaluate the PK of valemetostat in combination with R2 Exploratory Objective: Phase 2 * Evaluate the PFS of valemetostat in combination with R2 in R/R FL * Evaluate OS * Evaluate the effect of valemetostat in combination with R2 in R/R FL on epigenetic remodeling and gene expression * Evaluate changes in tumor/immune microenvironment * Evaluate pharmacodynamic profile of valemetostat
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
M D Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Loretta Nastoupil, MD
Affiliation: M.D. Anderson Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
